Jonathan Wolleben
Stock Analyst at Citizens
(4.53)
# 243
Out of 5,240 analysts
258
Total ratings
51.57%
Success rate
25.12%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALT Altimmune | Maintains: Market Outperform | $14 → $11 | $2.99 | +267.89% | 15 | May 14, 2026 | |
| PHVS Pharvaris | Maintains: Market Outperform | $75 → $74 | $32.40 | +128.40% | 13 | May 13, 2026 | |
| KLRS Kalaris Therapeutics | Maintains: Market Outperform | $26 → $25 | $5.38 | +364.68% | 2 | May 13, 2026 | |
| IRD Opus Genetics | Maintains: Market Outperform | $12 → $11 | $5.01 | +119.56% | 2 | May 13, 2026 | |
| MBX MBX Biosciences | Maintains: Market Outperform | $76 → $86 | $36.80 | +133.70% | 2 | May 12, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $97 → $95 | $37.28 | +154.83% | 21 | May 8, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Market Outperform | $25 → $28 | $9.72 | +188.21% | 11 | May 7, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $120 → $137 | $104.82 | +30.70% | 15 | May 6, 2026 | |
| BMEA Biomea Fusion | Initiates: Market Outperform | $9 | $1.48 | +508.11% | 1 | May 5, 2026 | |
| DBVT DBV Technologies | Maintains: Market Outperform | $47 → $55 | $19.77 | +178.20% | 18 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $132 | $110.00 | +20.00% | 15 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $28 | $26.81 | +4.46% | 7 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $152 → $155 | $94.87 | +63.39% | 9 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $180 → $170 | $57.08 | +197.83% | 10 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $120 → $113 | $38.00 | +197.37% | 12 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $63 | $42.63 | +47.78% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.20 | - | 3 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $527 → $745 | $529.56 | +40.68% | 15 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $35 | $7.49 | +367.29% | 9 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $11 → $10 | $5.29 | +89.04% | 10 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $9.35 | +210.16% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.82 | +371.20% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.66 | +381.93% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $0.84 | +1,695.87% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $8.11 | +134.42% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $45.82 | +9.12% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $32.04 | +180.90% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $133.78 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $438.52 | +10.60% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $64 | $13.95 | +358.78% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $33.10 | -27.49% | 1 | May 12, 2023 |
Altimmune
May 14, 2026
Maintains: Market Outperform
Price Target: $14 → $11
Current: $2.99
Upside: +267.89%
Pharvaris
May 13, 2026
Maintains: Market Outperform
Price Target: $75 → $74
Current: $32.40
Upside: +128.40%
Kalaris Therapeutics
May 13, 2026
Maintains: Market Outperform
Price Target: $26 → $25
Current: $5.38
Upside: +364.68%
Opus Genetics
May 13, 2026
Maintains: Market Outperform
Price Target: $12 → $11
Current: $5.01
Upside: +119.56%
MBX Biosciences
May 12, 2026
Maintains: Market Outperform
Price Target: $76 → $86
Current: $36.80
Upside: +133.70%
Crinetics Pharmaceuticals
May 8, 2026
Maintains: Market Outperform
Price Target: $97 → $95
Current: $37.28
Upside: +154.83%
BioCryst Pharmaceuticals
May 7, 2026
Maintains: Market Outperform
Price Target: $25 → $28
Current: $9.72
Upside: +188.21%
Protagonist Therapeutics
May 6, 2026
Maintains: Market Outperform
Price Target: $120 → $137
Current: $104.82
Upside: +30.70%
Biomea Fusion
May 5, 2026
Initiates: Market Outperform
Price Target: $9
Current: $1.48
Upside: +508.11%
DBV Technologies
May 1, 2026
Maintains: Market Outperform
Price Target: $47 → $55
Current: $19.77
Upside: +178.20%
Apr 21, 2026
Reiterates: Market Outperform
Price Target: $132
Current: $110.00
Upside: +20.00%
Mar 26, 2026
Maintains: Market Outperform
Price Target: $29 → $28
Current: $26.81
Upside: +4.46%
Mar 20, 2026
Maintains: Market Outperform
Price Target: $152 → $155
Current: $94.87
Upside: +63.39%
Mar 10, 2026
Maintains: Market Outperform
Price Target: $180 → $170
Current: $57.08
Upside: +197.83%
Feb 27, 2026
Maintains: Market Outperform
Price Target: $120 → $113
Current: $38.00
Upside: +197.37%
Feb 24, 2026
Initiates: Market Outperform
Price Target: $63
Current: $42.63
Upside: +47.78%
Jan 30, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $1.20
Upside: -
Jan 20, 2026
Maintains: Market Outperform
Price Target: $527 → $745
Current: $529.56
Upside: +40.68%
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $7.49
Upside: +367.29%
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $5.29
Upside: +89.04%
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $9.35
Upside: +210.16%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.82
Upside: +371.20%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $1.66
Upside: +381.93%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $0.84
Upside: +1,695.87%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $8.11
Upside: +134.42%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $45.82
Upside: +9.12%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $32.04
Upside: +180.90%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $133.78
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $438.52
Upside: +10.60%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $64
Current: $13.95
Upside: +358.78%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $33.10
Upside: -27.49%